Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
Authors' conclusion
D2T RA patients experienced higher disease activity despite maintaining b/tsDMARD therapy. Withdrawal rates due to inefficacy were higher in D2T RA.
Study context
- Population
- Patients with rheumatoid arthritis (RA) treated with b/tsDMARDs, Korean College of Rheumatology Biologics registry
- Participants
- 2,321 patients
- Exposure
- Difficult-to-treat (D2T) RA vs non-D2T RA
- D2T RAn = 271
- Outcome
- Prevalence of D2T RA
Methodological detailsKOBIO registry
- KOBIO registry
Main finding
As reported in the abstract
D2T RA
11.7%
271
- Lower age associated with D2T RA
- OR = 0.98, p < 0.001
- Longer disease duration
- OR = 1.06, p < 0.001
- Lower patient global assessment
- OR = 0.89, p = 0.045
- Higher SDAI
- OR = 1.06, p = 0.014
- Higher RAPID3
- OR = 1.06, p = 0.002
- Lower RF positivity
- OR = 0.65, p = 0.04
- Lower prior MTX use
- OR = 0.44, p = 0.008
- Lower prior SSZ use
- OR = 0.59, p = 0.003
- Lower prior LEF use
- OR = 0.67, p = 0.013
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Drug survival of b/tsDMARDsDid not differ | P = 0.35 |
| Withdrawal from b/tsDMARDs due to inefficacyMore frequent in D2T RA | P < 0.001 |
Drug survival of b/tsDMARDs
- Drug survival of individual b/tsDMARD differed between D2T and non-D2T RA after eight years
Original publication
Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry. Arthritis Res Ther. Published 19 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →